Bond.az White LogoBond.az Black Logo

Compass Point raises Nebius target to $260 on strong Q1

Compass Point raised Nebius price target to $260 on strong Q1 results. ARR and AI Cloud revenue surge. Read more on Bond.az.

David Wilson
ByDavid Wilson- Senior Editor
|
0

Compass Point raised its price target on Nebius Group (NASDAQ:NBIS) to $260 from $150 on Thursday while maintaining a Buy rating following the company’s first-quarter results.

Nebius reported group revenue increased 75% quarter-over-quarter to $399.0 million from $227.7 million. AI Cloud revenue rose 82% to $389.7 million and accounted for 98% of total Q1 revenue. The stock has rallied 474% over the past year, trading at $207.27 with a market cap of $53.1 billion.

Annual recurring revenue (ARR) increased to $1.92 billion. Adjusted EBITDA rose to $129.5 million, with AI Cloud adjusted EBITDA margin expanding to 45%. Deferred revenue hit $4.78 billion, while cash rose to $9.30 billion.

The company’s fiscal 2026 ARR target stands at $7 billion to $9 billion. Compass Point initiated coverage on February 18.

In other news, Nebius Group reported impressive Q1 2026 results, with EPS of $171.54 versus a forecast of -$62.2, and revenue of $32.44 billion, beating estimates. Analysts from Goldman Sachs, Wolfe Research, Citizens, and DA Davidson have issued positive ratings.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
Compass Point raises Nebius target to $260 on strong Q1 | Bond.az